今日，加科思药业在第五届RAS倡议研讨会上，以壁报的形式公布了旗下SHP2抑制剂JAB-3312和KRAS ...

马萨诸塞州剑桥 - 专注于开发肿瘤治疗药物的生物技术公司Immuneering Corporation ...

Immuneering recently announced positive initial Phase 2a data, including complete and partial responses, with IMM-1-104 in combination with ...

本文仅供医疗卫生等专业人士参考互动选择题：关于 Claudin 18.2：安斯泰来从 2019 年就开始参与靶向 Claudin 18.2 的 First-in-Class ...

磷酸化MAPK的激酶通常称为MAPKK，MEK行使这个MAPKK的功能；磷酸化MAPKK的激酶则通常称为MAPKKK，Raf可以认为是一种MAPKKK。 Ras-Raf-MEK-Erk通路只是GTP结合的 ...

Erasca develops cancer drugs that target the well-recognized RAS/MAPK pathway. This is a critical cell signaling pathway whose genetic mutations cause cancer. RAS proteins like KRAS transmit ...

is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or ...

决定依据《国家自然科学基金项目科研不端行为调查处理办法》第五十条第一项、第四项和第四十四条第四项，取消全成国家自然科学基金项目评审专家资格3年（2024年4月9日至2027年4月8日），取消全成国家自然科学基金项目申请和参与申请资格2年（2024年4月9日至2026年4月8日），给予全成通报批评。

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...

(Nasdaq: ERAS), a clinical-stage precision oncology company singularly f Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor for multiple RAS/MAPK pathway-driven tumors ...